PHASE I STUDY OF SAHA IN COMBINATION WITH BORTEZOMIB IN ADVANCED MALIGNANCIES

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 (from ClinicalTrials.gov网站） 用于化疗的药物，如伏立诺他，以不同的方式阻止肿瘤细胞的生长，要么杀死细胞，要么阻止它们分裂。硼替佐米可能通过阻断细胞生长所需的一些酶来阻止肿瘤细胞的生长。vorinostat与硼替佐米一起使用可能会杀死更多的肿瘤细胞。 这项I期试验正在研究伏立诺他和硼替佐米治疗转移性或不可切除的实体瘤患者的副作用和最佳剂量。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (from ClinicalTrials.gov website) Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with bortezomib may kill more tumor cells. This Phase I trial is studying the side effects and best dose of vorinostat and bortezomib in treating patients with metastatic or unresectable solid tumors.